|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NDUFB1 |
Gene summary for NDUFB1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NDUFB1 | Gene ID | 4707 |
| Gene name | NADH:ubiquinone oxidoreductase subunit B1 | |
| Gene Alias | CI-MNLL | |
| Cytomap | 14q32.12 | |
| Gene Type | protein-coding | GO ID | GO:0006091 | UniProtAcc | O75438 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 4707 | NDUFB1 | CA_HPV_1 | Human | Cervix | CC | 2.62e-06 | -1.06e-01 | 0.0264 |
| 4707 | NDUFB1 | CA_HPV_3 | Human | Cervix | CC | 2.31e-02 | -9.07e-02 | 0.0414 |
| 4707 | NDUFB1 | N_HPV_2 | Human | Cervix | N_HPV | 7.93e-06 | 2.39e-01 | -0.0131 |
| 4707 | NDUFB1 | CCI_1 | Human | Cervix | CC | 1.55e-08 | -7.16e-01 | 0.528 |
| 4707 | NDUFB1 | CCI_2 | Human | Cervix | CC | 3.52e-09 | -7.70e-01 | 0.5249 |
| 4707 | NDUFB1 | CCI_3 | Human | Cervix | CC | 3.49e-06 | -6.01e-01 | 0.516 |
| 4707 | NDUFB1 | CCII_1 | Human | Cervix | CC | 9.46e-23 | -8.12e-01 | 0.3249 |
| 4707 | NDUFB1 | Tumor | Human | Cervix | CC | 1.71e-14 | 4.44e-01 | 0.1241 |
| 4707 | NDUFB1 | sample3 | Human | Cervix | CC | 4.72e-11 | 3.39e-01 | 0.1387 |
| 4707 | NDUFB1 | L1 | Human | Cervix | CC | 1.66e-09 | -3.03e-01 | 0.0802 |
| 4707 | NDUFB1 | T3 | Human | Cervix | CC | 3.27e-08 | 3.24e-01 | 0.1389 |
| 4707 | NDUFB1 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.47e-05 | 3.10e-01 | -0.1808 |
| 4707 | NDUFB1 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.11e-05 | 3.78e-01 | -0.0811 |
| 4707 | NDUFB1 | HTA11_347_2000001011 | Human | Colorectum | AD | 6.29e-14 | 4.11e-01 | -0.1954 |
| 4707 | NDUFB1 | HTA11_3361_2000001011 | Human | Colorectum | AD | 2.08e-03 | 2.55e-01 | -0.1207 |
| 4707 | NDUFB1 | HTA11_83_2000001011 | Human | Colorectum | SER | 7.97e-09 | 4.77e-01 | -0.1526 |
| 4707 | NDUFB1 | HTA11_696_2000001011 | Human | Colorectum | AD | 3.09e-07 | 3.57e-01 | -0.1464 |
| 4707 | NDUFB1 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.18e-07 | 4.95e-01 | -0.059 |
| 4707 | NDUFB1 | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.83e-04 | 5.11e-01 | -0.1706 |
| 4707 | NDUFB1 | HTA11_5212_2000001011 | Human | Colorectum | AD | 9.43e-05 | 4.47e-01 | -0.2061 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00061195 | Stomach | SIM | oxidative phosphorylation | 31/708 | 141/18723 | 1.21e-15 | 7.15e-13 | 31 |
| GO:00229045 | Stomach | SIM | respiratory electron transport chain | 28/708 | 114/18723 | 1.41e-15 | 7.40e-13 | 28 |
| GO:000609151 | Stomach | SIM | generation of precursor metabolites and energy | 58/708 | 490/18723 | 1.10e-14 | 5.18e-12 | 58 |
| GO:00090605 | Stomach | SIM | aerobic respiration | 32/708 | 189/18723 | 9.30e-13 | 3.37e-10 | 32 |
| GO:00453335 | Stomach | SIM | cellular respiration | 34/708 | 230/18723 | 9.47e-12 | 3.19e-09 | 34 |
| GO:00159805 | Stomach | SIM | energy derivation by oxidation of organic compounds | 40/708 | 318/18723 | 2.55e-11 | 7.53e-09 | 40 |
| GO:00061205 | Stomach | SIM | mitochondrial electron transport, NADH to ubiquinone | 16/708 | 51/18723 | 3.08e-11 | 8.56e-09 | 16 |
| GO:00102575 | Stomach | SIM | NADH dehydrogenase complex assembly | 15/708 | 57/18723 | 2.01e-09 | 2.79e-07 | 15 |
| GO:00329815 | Stomach | SIM | mitochondrial respiratory chain complex I assembly | 15/708 | 57/18723 | 2.01e-09 | 2.79e-07 | 15 |
| GO:00331085 | Stomach | SIM | mitochondrial respiratory chain complex assembly | 17/708 | 93/18723 | 6.41e-08 | 6.30e-06 | 17 |
| GO:004277327 | Thyroid | HT | ATP synthesis coupled electron transport | 37/1272 | 95/18723 | 2.53e-19 | 4.69e-16 | 37 |
| GO:004277527 | Thyroid | HT | mitochondrial ATP synthesis coupled electron transport | 37/1272 | 95/18723 | 2.53e-19 | 4.69e-16 | 37 |
| GO:001964627 | Thyroid | HT | aerobic electron transport chain | 35/1272 | 87/18723 | 6.82e-19 | 7.59e-16 | 35 |
| GO:002290427 | Thyroid | HT | respiratory electron transport chain | 38/1272 | 114/18723 | 4.07e-17 | 2.83e-14 | 38 |
| GO:000611927 | Thyroid | HT | oxidative phosphorylation | 42/1272 | 141/18723 | 9.39e-17 | 5.80e-14 | 42 |
| GO:004603429 | Thyroid | HT | ATP metabolic process | 61/1272 | 277/18723 | 1.37e-16 | 7.63e-14 | 61 |
| GO:000906027 | Thyroid | HT | aerobic respiration | 47/1272 | 189/18723 | 3.35e-15 | 1.10e-12 | 47 |
| GO:002290027 | Thyroid | HT | electron transport chain | 44/1272 | 175/18723 | 1.67e-14 | 4.89e-12 | 44 |
| GO:004533327 | Thyroid | HT | cellular respiration | 49/1272 | 230/18723 | 5.19e-13 | 1.26e-10 | 49 |
| GO:001598027 | Thyroid | HT | energy derivation by oxidation of organic compounds | 57/1272 | 318/18723 | 1.27e-11 | 2.20e-09 | 57 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0520820 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
| hsa0501220 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
| hsa0019018 | Cervix | CC | Oxidative phosphorylation | 64/1267 | 134/8465 | 1.25e-19 | 8.07e-18 | 4.77e-18 | 64 |
| hsa0502018 | Cervix | CC | Prion disease | 98/1267 | 273/8465 | 2.64e-18 | 1.42e-16 | 8.42e-17 | 98 |
| hsa0541520 | Cervix | CC | Diabetic cardiomyopathy | 76/1267 | 203/8465 | 1.40e-15 | 6.46e-14 | 3.82e-14 | 76 |
| hsa0501018 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
| hsa0501618 | Cervix | CC | Huntington disease | 94/1267 | 306/8465 | 8.49e-13 | 3.06e-11 | 1.81e-11 | 94 |
| hsa0502218 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
| hsa0493218 | Cervix | CC | Non-alcoholic fatty liver disease | 58/1267 | 155/8465 | 3.58e-12 | 1.05e-10 | 6.23e-11 | 58 |
| hsa0471420 | Cervix | CC | Thermogenesis | 76/1267 | 232/8465 | 4.29e-12 | 1.16e-10 | 6.85e-11 | 76 |
| hsa0501418 | Cervix | CC | Amyotrophic lateral sclerosis | 103/1267 | 364/8465 | 1.79e-11 | 4.47e-10 | 2.64e-10 | 103 |
| hsa0472318 | Cervix | CC | Retrograde endocannabinoid signaling | 42/1267 | 148/8465 | 1.79e-05 | 1.42e-04 | 8.40e-05 | 42 |
| hsa05208110 | Cervix | CC | Chemical carcinogenesis - reactive oxygen species | 92/1267 | 223/8465 | 4.71e-22 | 5.09e-20 | 3.01e-20 | 92 |
| hsa05012110 | Cervix | CC | Parkinson disease | 102/1267 | 266/8465 | 1.81e-21 | 1.47e-19 | 8.66e-20 | 102 |
| hsa0019019 | Cervix | CC | Oxidative phosphorylation | 64/1267 | 134/8465 | 1.25e-19 | 8.07e-18 | 4.77e-18 | 64 |
| hsa0502019 | Cervix | CC | Prion disease | 98/1267 | 273/8465 | 2.64e-18 | 1.42e-16 | 8.42e-17 | 98 |
| hsa05415110 | Cervix | CC | Diabetic cardiomyopathy | 76/1267 | 203/8465 | 1.40e-15 | 6.46e-14 | 3.82e-14 | 76 |
| hsa0501019 | Cervix | CC | Alzheimer disease | 113/1267 | 384/8465 | 9.67e-14 | 3.92e-12 | 2.32e-12 | 113 |
| hsa0501619 | Cervix | CC | Huntington disease | 94/1267 | 306/8465 | 8.49e-13 | 3.06e-11 | 1.81e-11 | 94 |
| hsa0502219 | Cervix | CC | Pathways of neurodegeneration - multiple diseases | 128/1267 | 476/8465 | 2.87e-12 | 9.29e-11 | 5.50e-11 | 128 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NDUFB1 | SNV | Missense_Mutation | c.77N>T | p.Ala26Val | p.A26V | O75438 | protein_coding | tolerated_low_confidence(0.24) | benign(0.071) | TCGA-AA-3672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| NDUFB1 | SNV | Missense_Mutation | novel | c.26N>T | p.Ala9Val | p.A9V | O75438 | protein_coding | tolerated_low_confidence(0.11) | benign(0.003) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| NDUFB1 | SNV | Missense_Mutation | c.174N>A | p.His58Gln | p.H58Q | O75438 | protein_coding | tolerated(0.14) | benign(0.148) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NDUFB1 | SNV | Missense_Mutation | c.222N>T | p.Leu74Phe | p.L74F | O75438 | protein_coding | tolerated(0.06) | possibly_damaging(0.698) | TCGA-86-8073-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| NDUFB1 | SNV | Missense_Mutation | rs768770418 | c.76N>T | p.Ala26Ser | p.A26S | O75438 | protein_coding | tolerated_low_confidence(0.2) | benign(0.082) | TCGA-77-8150-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
| NDUFB1 | SNV | Missense_Mutation | novel | c.167N>T | p.Arg56Leu | p.R56L | O75438 | protein_coding | deleterious(0.01) | probably_damaging(0.973) | TCGA-CQ-6219-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| NDUFB1 | SNV | Missense_Mutation | rs780594896 | c.139A>G | p.Ile47Val | p.I47V | O75438 | protein_coding | tolerated(0.72) | benign(0.003) | TCGA-F7-A622-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| NDUFB1 | SNV | Missense_Mutation | novel | c.233G>T | p.Ser78Ile | p.S78I | O75438 | protein_coding | deleterious(0) | benign(0.347) | TCGA-BR-8058-01 | Stomach | stomach adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 4707 | NDUFB1 | ENZYME | inhibitor | CHEMBL3545320 | ME-344 | |
| 4707 | NDUFB1 | ENZYME | inhibitor | CHEMBL3545135 | NV-128 | |
| 4707 | NDUFB1 | ENZYME | inhibitor | CHEMBL1703 | METFORMIN HYDROCHLORIDE |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |